comparemela.com

Latest Breaking News On - Prnewswire bugworks research inc - Page 1 : comparemela.com

Bugworks Research Inc to Present Eight Posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023, in Copenhagen, Denmark

BANGALORE, India and DELAWARE CITY, Del. and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark. The eight posters highlight data from the microbiological and efficacy studies of the clinical candidate, BWC0977 that exhibits broad-spectrum activity against a globally, diverse panel of Gram-positive, Gram-negative and biothreat pathogens. Additionally, data from a range of studies, including in vitro biochemical assays, in vitro resistance frequency studies, minimum inhibitory concentration (MIC90) data against multi-drug resistant clinical isolates from around the world, and in vivo efficacy data in mice and rat models of infection will be presented. These studies were conducted in collaboration wi

Bugworks Research Inc and Cytecare Cancer Hospitals announce collaboration to accelerate the development of cutting-edge Immuno-oncology therapies

Bugworks - a US, India and Australia based start-up with globally recognized expertise in drug discovery, has set up a dedicated Immuno-oncology ex vivo.

Bugworks secures funding from US Government s Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats

Bugworks secures funding from US Government s Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats News provided by Share this article Share this article BANGALORE, India, April 26, 2021 /PRNewswire/ Bugworks Research, Inc ( Bugworks ), secures funding from the Defense Threat Reduction Agency (DTRA) to support development of its novel broad-spectrum antibiotic BWC0977, against the most critical bacterial biothreats. DTRA will provide funding, through its Bacterial Rapid Acquisition Platform program, to support the nonclinical biodefense aspects of the development of BWC0977, including execution of in vivo efficacy studies to test BWC0977 against biothreat bacterial pathogens, beginning with

Bugworks secures funding from US Government s Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats

Bugworks secures funding from US Government s Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.